Aurinia Pharmaceuticals Inc. (Alberta, Canada) is organized under the Business Corporations Act. Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on providing therapies to treat target patient groups with unmet medical needs affected by autoimmune, renal and rare diseases. In January 2021, Aurinia Pharma launched the first FDA-approved oral drug LUPKYNIS (voclosporin) for the treatment of adult patients with active LN. LUPKYNIS is an oral CNI immunosuppressant that has been shown to improve near- and long-term outcomes of LN when used in combination with mycophenolate mofetil (MMF) (although MMF is not currently approved) and steroids. By inhibiting calcineurin, LUPKYNIS reduces cytokine activation, blocks interleukin IL-2 expression and T cell-mediated immune response. LUPKYNIS may also stabilize podocytes, thereby preventing proteinuria. 

AUPH

AUPH Profile